Background: Mechanical ventilation is a life-saving intervention used to provide adequate pulmonary ventilation in patients suffering from respiratory failure. However, prolonged mechanical ventilation is associated with significant diaphragmatic weakness resulting from both myofiber atrophy and contractile dysfunction. Although several signaling pathways contribute to diaphragm weakness during mechanical ventilation, it is established that oxidative stress is required for diaphragmatic weakness to occur. Therefore, identifying the site(s) of mechanical ventilationinduced reactive oxygen species production in the diaphragm is important.
M echanical ventilation (MV)
is used clinically to achieve adequate pulmonary gas exchange in patients suffering from hypoxemia and in patients who are incapable of maintaining sufficient alveolar ventilation. Common indications for MV include respiratory failure, heart failure, surgery, drug overdose, and spinal cord injuries (1) . Even though MV is a life-saving measure for patients in respiratory failure, problems with wean-ing patients from the ventilator are common. Indeed, weaning difficulties are an important clinical problem as 20% to 30% of mechanically ventilated patients experience weaning difficulties (2) . Although the failure to wean patients may be due to several factors, respiratory muscle weakness is predicted to play an important role (3) . In reference to the causes of respiratory muscle weakness, numerous studies demonstrate that prolonged MV (Ͼ12 hrs) promotes a rapid development of diaphragmatic weakness due to both contractile dysfunction and atrophy (4 -8) .
Oxidative damage to diaphragmatic myofibrillar lipids and proteins is a hallmark of MV-induced diaphragmatic weakness (9, 10) . Importantly, our work reveals that prevention of MV-induced oxidative stress via antioxidants can avert the diaphragmatic atrophy and contractile dysfunction that occurs during prolonged MV (11, 12) . These findings indicate that the MV-induced production of reactive oxygen species (ROS) is an essential upstream trigger to initiate signaling events leading to diaphragmatic weakness. To develop an appropriate therapeutic target to prevent MV-induced diaphragmatic weakness, it is important to identify the site(s) of ROS production in the diaphragm during prolonged MV. Previous efforts to identify the location of MVinduced ROS generation in the diaphragm indicate that xanthine oxidase, reduced nicotinamide adenine dinucle-otide phosphate oxidase, and mitochondria produce ROS during prolonged MV (13) (14) (15) . However, inhibition of xanthine oxidase activity does not completely protect the diaphragm from MVinduced oxidative stress and atrophy (15) . Furthermore, although prolonged MV activates nicotinamide adenine dinucleotide phosphate oxidase in the diaphragm, the MV-induced increase in nicotinamide adenine dinucleotide phosphate activity is small (i.e., 5%) (14) . In contrast, our recent work indicates that prolonged MV results in a significant increase in diaphragmatic mitochondrial ROS emission (13) . Together, these findings suggest that mitochondria may be an important source of ROS production in the diaphragm during prolonged MV. Therefore, to determine the physiologic significance of mitochondrial ROS emission in the development of MV-induced diaphragmatic weakness, these experiments employed a mitochondria-targeted antioxidant (SS-31) to test the hypothesis that mitochondrial ROS emission plays a dominant role in MV-induced diaphragmatic oxidative stress, proteolysis, atrophy, and contractile dysfunction. SS-31 (D-Arg-2Ј,6Ј-dimethyl-Tyr-Lys-Phe-NH 2 ) is a synthetic aromatic cationic tetrapeptide that has been shown to selectively target and concentrate ϳ1000-fold in the inner mitochondrial membrane (16) . Tyrosine and tyrosine-containing peptides can scavenge oxyradicals (17) , and the mitochondrial targeting of SS-31 provides selective scavenging of mitochondrial oxyradicals. SS-31 has no effect on nicotinamide adenine dinucleotide phosphate oxidase activity (unpublished observations). Numerous studies in isolated mitochondria, cultured cells, and animal models have shown that SS-31 can selectively scavenge mitochondrial ROS and protect mitochondrial function (18, 19) . Furthermore, the protection provided by SS-31 is similar to that achieved by overexpression of catalase targeted to mitochondria (18) .
METHODS

Animals and Institutional Approval
Young adult (ϳ6 months old) female Sprague-Dawley rats were used in these experiments. The Institutional Animal Care and Use Committee of the University of Florida (Gainesville, FL) approved these experiments.
Experimental Design
To investigate the role that mitochondrial ROS emission plays in MV-induced diaphragmatic weakness, we performed two separate experiments. Experiment 1. This experiment was performed to determine the effect of a mitochondria-targeted antioxidant (SS-31) on diaphragmatic contractile function, fiber crosssectional area (CSA), and mitochondrial function in awake and spontaneously breathing rats. Animals (n ϭ 6/group) were randomly assigned into one of two experimental groups: 1) control group, injected with saline (intraperitoneally) at 3-hr intervals for 12 hrs, and 2) mitochondrial antioxidant group, injected (intraperitoneally) with SS-31 every 3 hrs for 12 hrs. At the completion of the 12-hr treatment periods, we measured diaphragmatic contractile function, fiber CSA, mitochondrial ROS emission, and mitochondrial respiratory function. Our results reveal that compared to the control, treatment of spontaneous breathing animals with SS-31 did not alter any of these dependent measures (see Results). Therefore, we then performed a second experiment using SS-31 to determine the role that mitochondrial ROS emission plays in MV-induced diaphragmatic weakness during 12 hrs of MV.
Experiment 2. To test the hypothesis that mitochondrial ROS emission plays a critical role in MV-induced diaphragmatic oxidative stress and weakness, rats were randomly assigned to one of three experimental groups (n ϭ 12/group): 1) an acutely anesthetized control group, 2) a 12-hr MV group, and 3) a 12-hr MV group treated with the mitochondria-targeted antioxidant SS-31. Because of the large tissue requirement for our numerous dependent measures, six animals from each experimental group were used for the mitochondrial measures and the remaining six animals in each group were employed in all other biochemical assays.
Experimental Protocol for Experiment 2
Acutely Anesthetized Controls. Animals in the control group were acutely anesthetized with an intraperitoneal injection of sodium pentobarbital (60 mg/kg of body weight). After a surgical plane of anesthesia was reached, the diaphragms were quickly removed. In one group of animals (n ϭ 6), a strip of the medial costal diaphragm was immediately used for in vitro contractile measurements, a separate section was stored for histologic measurements, and the remaining portions of the costal diaphragm were rapidly frozen in liquid nitrogen and stored at Ϫ80°C for subsequent biochemical analyses. In a second group of animals (n ϭ 6), the entire costal diaphragm was rapidly removed and used to isolate mitochondria for measurements of mitochondrial respiration and ROS emission.
MV. All surgical procedures were performed using aseptic techniques. Animals in the MV groups were anesthetized with an intraperitoneal injection of sodium pentobarbital (60 mg/kg of body weight), tracheostomized, and mechanically ventilated with a pressure-controlled ventilator (Servo Ventilator 300, Siemens, Munich, Germany) for 12 hrs with the following settings: upper airway pressure limit, 20 cm H 2 O; typical pressure generation above the positive end-expiratory pressure, 6 -9 cm H 2 O; respiratory rate, 80 breaths/min; positive end-expiratory pressure, 1 cm H 2 O.
The carotid artery was cannulated to permit the continuous measurement of blood pressure and the collection of blood during the protocol. Arterial blood samples (100 L per sample) were removed periodically and analyzed for arterial PO 2 , PCO 2 , and pH using an electronic blood-gas analyzer (GEM Premier 3000, Instrumentation Laboratory, Lexington, MA). Ventilator adjustments were made if arterial PCO 2 exceeded 40 mm Hg. Arterial PO 2 was maintained at Ͼ60 mm Hg throughout the experiment by increasing the FIO 2 (22% to 26% oxygen).
A venous catheter was inserted into the jugular vein for continuous infusion of sodium pentobarbital (ϳ10 mg/kg/hr) and fluid replacement. The body temperature was maintained at 37°C by use of a heating blanket, and the heart rate was monitored via a lead II electrocardiograph. Continuous care during the MV protocol included lubricating the eyes, expressing the bladder, removing airway mucus, rotating the animal, and passively moving the limbs. Animals also received an intramuscular injection of glycopyrrolate (0.08 mg/kg, loading dose, and 0.04 mg/kg) every 2 hrs during MV to reduce airway secretions. Upon completion of MV, diaphragm removal and storage was completed using the same protocol as previously described for the controls.
Mitochondria-Targeted Antioxidant: Chemical Details and Experimental Delivery. We selected a mitochondria-targeted antioxidant designated as "SS-31" for use in the current experiments. This molecule belongs to a family of small, water-soluble peptides that contain an alternating aromatic-cationic motif and selectively target the mitochondria (20) .
In experiment 1, the mitochondriatargeted antioxidant SS-31 was dissolved in saline and delivered via four subcutaneous injections during the 12-hr experimental period. The first bolus (loading) dose (3 mg/kg, subcutaneous injection) was administered at the onset of the experiment. We then delivered SS-31 (0.05 mg/kg/hr) via subcutane-ous injections staged every 3 hrs during the 12-hr experiment. Importantly, animals in experiment 1 received the same total amount of SS-31 during 12 hrs as the animals in experiment 2.
In experiment 2, the mitochondria-targeted antioxidant SS-31 was dissolved in saline and delivered in a bolus (loading) dose (3 mg/kg, subcutaneous injection) 15 mins before initiation of MV. A constant intravenous infusion (0.05 mg/kg/hr) of SS-31 was maintained throughout MV.
Biochemical Measures
Isolation of Mitochondria. Approximately 500 mg of costal diaphragm muscle was used to isolate diaphragmatic mitochondria using the methods of Makinen and Lee (21) with minor modifications (13) .
Mitochondrial Respiration. Mitochondrial oxygen consumption was measured using previously described techniques (13) . The maximal respiration (state 3) and state 4 respiration (basal respiration) were measured as described previously (22) . The respiratory control ratio was calculated by dividing state 3 respiration by state 4 respiration.
Mitochondrial ROS Emission. Diaphragmatic mitochondrial ROS emission was determined using Amplex Red (Molecular Probes, Eugene, OR). Details of this assay have been described previously (13) . Mitochondrial ROS production was measured using the creatine kinase energy clamp technique to maintain respiration at the steady state using previously described methods (23) .
Western Blot Analysis. Protein abundance was determined in diaphragm samples via Western blot analysis using previously described methods (24) . After electrophoresis, the proteins were transferred to nitrocellulose membranes and incubated with primary antibodies directed against the protein of interest. 4-Hydroxynonenal (Abcam, Cambridge, U.K.) was probed as a measurement indicative of oxidative stress while proteolytic activity was assessed by analyzing MuRF-1 (ECM Biosciences, Versailles, KY), atrogin-1 (ECM Biosciences), cleaved (active) calpain-1 (Cell Signaling Technology, Danvers, MA), and cleaved (active) caspase-3 (Cell Signaling Technology). Furthermore, ␣-II spectrin (Santa Cruz Biotechnology, Santa Cruz, CA) calpain-specific cleavage (145-kDa cleavage product) and caspase-3specific cleavage (120-kDa cleavage product) were measured to obtain an additional measurement of both calpain-1 and caspase-3 activity during MV. The protein abundance of actin (Santa Cruz Biotechnology) was measured as an index of overall proteolysis in the diaphragm. Finally, ␣-tubulin was used as a loading control for all Western blots to verify equal protein loading and transfer.
Assessment of Protein Oxidation Via Reactive Carbonyl Derivatives. The levels of reactive carbonyl derivatives in the myofibrillar protein samples were assessed as an index of the magnitude of protein modification. This was accomplished using the Oxyblot oxidized protein detection kit from Chemicon International (Temecula, CA) as described previously (13) .
Ribonucleic Acid Isolation and Complementary Deoxyribonucleic Acid Synthesis. Total ribonucleic acid (RNA) was isolated from muscle tissue with TRIzol reagent (Life Technologies, Carlsbad, CA) according to the manufacturer's instructions. The RNA content (g/mg of muscle) was evaluated by spectrophotometry. RNA (5 g) was then reverse transcribed with the Superscript III firststrand synthesis system for real-time polymerase chain reaction (Life Technologies) using oligo(dT)20 primers and the protocol outlined by the manufacturer.
Real-Time Polymerase Chain Reaction. A 1 L volume of complementary deoxyribonucleic acid was added to a 25 L polymerase chain reaction for real-time polymerase chain reaction using Taqman chemistry and the ABI Prism 7000 sequence detection system (ABI, Foster City, CA). Relative quantification of gene expression was performed using the comparative computed tomography method (ABI, User Bulletin #2). ␤-Glucuronidase, a lysosomal glycoside hydrolase, was chosen as the reference gene on the basis of previous work showing unchanged expression with our experimental manipulations (25) . MAFbx (GenBank NM AY059628, National Center for Biotechnology Information, Bethesda, MD) and MuRF-1 (GenBank NM AY059627 and NM BC061824) messenger RNA (mRNA) transcripts were assayed using predesigned rat primer and probe sequences commercially available from Applied Biosystems (Carlsbad, CA; Assays-on-Demand).
20S Proteasome Activity. A section of the ventral costal diaphragm was homogenized, and the in vitro chymotrypsin-like activity (substrate Z-Leu-Leu-Leu-AMC) of the 20S proteasome was measured fluorometrically using techniques described by Stein and coworkers (26) .
Functional Measures: Measurement of in Vitro Diaphragmatic Contractile Properties
At the completion of the experimental periods, the entire diaphragm was removed and placed in a dissecting chamber containing a Krebs-Hensleit solution equilibrated with 95% oxygen-5% carbon dioxide gas. A muscle strip (ϳ3 mm wide) was suspended vertically between two lightweight Plexiglas clamps (Altuglas International, Philadelphia, PA) with one end connected to an isometric force transducer (FT-03, Grass Instruments, Quincy, MA) within a jacketed tissue bath. The muscle was electrically stimulated to contract, and the force output was recorded via a computerized data-acquisition system as previously described (5) . For comparative purposes, diaphragmatic force production was normalized to CSA (i.e., specific force production).
Histologic Measures: Myofiber CSA
Sections from frozen diaphragm samples were cut at 10 m using a cryotome (Shandon, Pittsburgh, PA) and stained for dystrophin, myosin heavy chain I, and myosin heavy chain type IIa proteins for fiber CSA analysis as described previously (12) . CSA was determined using Scion software (National Institutes of Health, Bethesda, MD).
Statistical Analysis
Comparisons between groups for each biochemical dependent variable were made by a one-way analysis of variance, and when appro- priate, a Tukey honestly significant difference test was performed post hoc. Furthermore, using a one-way analysis of variance, we compared the group differences in diaphragmatic specific force production at each stimulation frequency. If statistically significant differences existed, we then performed a Tukey honestly significant difference post hoc test to determine which groups differed. Significance was established at p Ͻ .05. Data are presented as means Ϯ SEM.
RESULTS
SS-31 Does Not Impact Diaphragmatic Fiber CSA or Function in Spontaneously Breathing Animals
To determine the impact of the mitochondrial antioxidant SS-31 on diaphragmatic contractile function, fiber CSA, and mitochondrial function in awake and spontaneously breathing rats, we treated animals for 12 hrs with the same levels of SS-31 that were provided to the mechanically ventilated animals during the 12-hr MV period. Our results indicate that compared to control animals, the treatment of animals with SS-31 does not influence diaphragmatic fiber size, contractile function, mitochondrial ROS emission, and mitochondrial respiratory function (Tables 1-3) .
Physiologic Responses to Prolonged MV
To determine whether our MV protocol was successful in maintaining homeostasis, we measured arterial blood pressures, arterial PCO 2 , arterial PO 2 , and arterial pH in all animals at the beginning of the experiments and at various time intervals during MV. Our results confirm that arterial blood pressure and blood-gas/pH homeostasis were wellmaintained during MV (Table 4 ).
Our data also indicate that our animals did not develop infection during MV as evidenced by the observations that our MV animals were afebrile, no detectable bacteria were in the blood, and postmortem examination of the lungs and peritoneal cavity yielded no detectable abnormalities.
A Mitochondria-Targeted Antioxidant Impedes MV-Induced ROS Emission From Diaphragmatic Mitochondria
To determine whether mitochondria-derived ROS emission is required Values are means Ϯ SEM. No significant differences existed between the two experimental groups in any of these physiologic variables. for MV-induced oxidative damage, contractile dysfunction, and atrophy in the diaphragm, we treated rats with SS-31 to prevent MV-induced ROS emission from diaphragm mitochondria. Our results indicate that treatment with SS-31 prevented the MV-induced increase in diaphragmatic mitochondrial hydrogen peroxide release during both state 3 and state 4 respiration (Fig. 1) .
Our prior work indicates that prolonged MV results in damage to mitochondria as indicated by impaired coupling (i.e., lower respiratory control ratios) in mitochondria isolated from the diaphragm of MV animals (13) . Therefore, we asked whether treatment of animals with SS-31 would protect diaphragmatic mitochondria from MV-induced mitochondrial uncoupling. As shown in Table  5 , treatment with SS-31 was successful in averting diaphragmatic mitochondrial uncoupling that occurs following prolonged MV.
MV-Induced Oxidative Stress Is Mediated by Mitochondrial ROS Emission
To determine whether mitochondrial ROS emission is required for MV-induced oxidative stress in the diaphragm, we measured two biomarkers of oxidative damage. Our results reveal that treatment of animals with SS-31 protected the diaphragm against the ROS-induced increase in both protein carbonyls and 4-hydroxynonenal-conjugated proteins normally associated with prolonged MV (Fig. 2 ).
Increased Mitochondrial ROS Emission Promotes MV-Induced Diaphragmatic Contractile Dysfunction and Fiber Atrophy
To determine the role that mitochondrial ROS emission plays in MVinduced diaphragmatic contractile dysfunction, we measured diaphragmatic contractile performance in vitro using strips of diaphragm muscle obtained from control animals, MV animals, and MV animals treated with SS-31. Prevention of MV-induced mitochondrial ROS emission using SS-31 was successful in diminishing the normally observed MVinduced diaphragmatic contractile dysfunction. Note, however, that treatment of animals with SS-31 did not com-pletely retard the detrimental effects of prolonged MV on diaphragmatic force production at stimulation frequencies Ͼ15 Hz (Fig. 3) . Nonetheless, while treatment with SS-31 did not completely eliminate the MV-induced diaphragmatic contractile dysfunction, the difference in diaphragmatic force gen-eration between controls and MV animals treated with SS-31 were small (ϳ5% to 6%) at all stimulation frequencies. At present, it is unclear if these small differences are physiologically significant.
Previous work reveals that MVinduced oxidative stress is a require- ment for the diaphragmatic fiber atrophy that is associated with prolonged MV (11, 12) . Therefore, we asked if MVinduced mitochondrial ROS emission is a requirement for MV-induced diaphragmatic atrophy. Myofiber CSA was determined for individual fiber types for all treatment groups. Our data reveal that prevention of the MV-induced increase in mitochondrial ROS emission protects the diaphragm from MVinduced fiber atrophy (Fig. 4 ).
MV-Induced Mitochondrial ROS Emission Promotes Diaphragmatic Protease Activation and Proteolysis
Ubiquitin-Proteasome System. The ubiquitin-proteasome system of proteolysis is activated in the diaphragm during prolonged MV and, therefore, is predicted to contribute to MV-induced diaphragmatic protein breakdown. Therefore, we measured 20S proteasome activity along with both mRNA and protein levels of two important muscle-specific E3 ligases (i.e., atrogin-1/MAFbx and MuRF-1) in the diaphragm. Our results reveal that prevention of MV-induced mitochondrial ROS release via SS-31 prevented the MVinduced increase in 20S proteasome activity in the diaphragm (Fig. 5A) . Furthermore, our data indicate that prolonged MV resulted in a significant increase in atrogin-1/MAFbx mRNA levels in the diaphragm of both MV groups; however, treatment of animals with SS-31 significantly blunted the MVinduced increase in atrogin-1/MAFbx protein levels in the diaphragm (Fig.  5B ). Furthermore, prolonged MV resulted in a significant increase in MuRF-1 mRNA levels in the diaphragm, and although MuRF-1 protein levels tended to increase in the diaphragm of mechanically ventilated animals, these differences did not reach significance (Fig. 5C ).
Calpain and Caspase-3 Activation. Our prior work indicates that calpain and caspase-3 activation in the diaphragm plays an important role in MVinduced diaphragmatic atrophy and contractile dysfunction (24, 27) . We assayed diaphragmatic calpain and caspase-3 activity using two different but complementary methods. First, we determined active calpain-1 and caspase-3 levels in the muscle via Western blotting to detect the cleaved and active forms of calpain-1 and caspase-3 ( Fig. 6 ). We also measured the calpainand caspase-3-specific degradation products of ␣-II spectrin as these breakdown products provide a signature product in vivo that can be detected via Western analysis (Fig. 7) . This technique provides an index of in vivo calpain and caspase-3 activity in the diaphragm over a prolonged period of time during MV. Collectively, our results reveal that treatment of animals with SS-31 protected the diaphragm against the MV-induced activation of both calpain ( Figs. 6A and 7A ) and caspase-3 ( Figs. 6B and 7B) .
Mitochondria-Targeted Antioxidants Protect Against MV-Induced Diaphragmatic Proteolysis. After demonstrating that prevention of MV-induced increases in mitochondrial ROS emission protects the diaphragm against protease activation, we then measured the relative abundance of the sarcomeric protein actin in the diaphragm as a marker of disuse-induced muscle proteolysis (28) . Our results reveal that, compared to diaphragm muscle from both control and MV-SS animals, the actin abundance was significantly reduced in diaphragm muscle from animals exposed to prolonged MV without mitochondrial antioxidants (Fig. 8) . Therefore, prevention of MV-induced mitochondrial ROS emission protected against both MV-induced protease activation and diaphragmatic proteolysis.
DISCUSSION
Overview of Major Findings. These experiments provide several new and important findings relative to the mechanism(s) responsible for the rapid onset of MV-induced diaphragmatic atrophy and contractile dysfunction. First, our data reveal that mitochondria are a dominant source of oxidant production in the diaphragm during prolonged MV. Second, our findings clearly demonstrate that mitochondrial ROS emission is a required upstream signal for the MV-induced activation of key proteases (i.e., calpain and caspase-3) in the diaphragm. Finally, our results also show that prevention of MV-induced increases in mitochondrial ROS emission in the diaphragm can protect the diaphragm from MV-induced diaphragmatic atrophy and contractile dysfunction. A critique of our experimental model and a detailed discussion of the significance of these results follow.
Critique of Experimental Model. Because of the invasive nature of obtaining diaphragm muscle samples from humans, an animal model is required to perform mechanistic experiments to explore the signaling pathways that promote MV-induced diaphragmatic weak-ness. We selected the rat as the experimental animal in these experiments for several reasons. First, the anatomical features and function of the rat diaphragm are similar to those of the human diaphragm (29, 30) . Second, the fiber type compositions of the rat and human costal diaphragms are comparable (4, 31, 32) . Finally, the time courses of MV-induced atrophy in the rat and human diaphragms are also similar (4, 10) .
Investigating the role of mitochondrial ROS emission as a signaling molecule in the diaphragm requires a mitochondria-targeted antioxidant to "buffer" this increased ROS emission. To achieve this goal, we selected a new and innovative mitochondria-targeted antioxidant (i.e., SS-31) for use in the current experiments. This compound selectively concentrates in the mitochondria and can provide radical scavenging of hydrogen peroxide, hydroxyl radical, and peroxynitrite on a dosedependent basis (20, 33) . Importantly, SS-31 does not alter the mitochondrial membrane potential (20) , and our results reveal that SS-31 does not influence diaphragmatic mitochondrial function, myofiber size, and contractile function. Because of these collective properties, this mitochondria-targeted antioxidant is ideal for use in our current experiments.
Our experiments investigated the impact of prolonged MV on diaphragm mitochondria function using isolated mitochondria. The isolation of mitochondria from diaphragm muscle disrupts the normal in vivo arrangement of these organelles as skeletal muscle mitochondria in vivo are arranged in an interconnected reticulum (34, 35) . This in vivo architecture of muscle mitochondria suggests that this structural pattern may have functional implications for these organelles (36) . It follows that isolation of muscle mitochondria would disrupt this normal structure and potentially impair mitochondrial function. Nonetheless, in the current study, the respiratory control ratios of isolated mitochondria from control animals are similar to those reported in preparations of permeabilized rat muscle fibers that permit mitochondria to remain in their reticular structure (37) . This observation is consistent with the notion that careful isolation of skeletal muscle mitochondria does not alter normal mitochondrial function and coupling.
Mitochondria Are a Key Source of MV-Induced ROS Production in the Diaphragm. It is well established that prolonged MV results in increased ROS production in the diaphragm, disturbed redox signaling, and oxidative damage to diaphragmatic biomolecules (9, 10, 38) . However, the primary site(s) of MVinduced ROS production in the diaphragm remain unknown. To investigate the role that mitochondria play in MV-induced ROS production in the diaphragm, we treated animals with SS-31 and isolated mitochondria from the diaphragm of control and mechanically ventilated animals with and without the mitochondrial antioxidant. Our results clearly indicate that prolonged MV promotes a significant increase in mitochondrial ROS emission and that treatment of animals with SS-31 prevents this increase (Fig. 1 ). Furthermore, providing animals with SS-31 prevented the MV-mediated oxidative damage to diaphragmatic proteins (Fig.  3) . Collectively, these data indicate that mitochondrial ROS are the dominant contributor to oxidative damage to the diaphragm during prolonged MV.
Mitochondrial ROS Emission Is Required for MV-Induced Diaphragmatic Atrophy and Contractile Dysfunction.
Our prior work reveals that MV-induced oxidative stress is a requirement for MV-induced diaphragmatic atrophy and contractile dysfunction (11, 12) . Furthermore, we have shown that MVinduced oxidative stress is essential for the activation of key proteases in the diaphragm, including the 20S proteasome, calpain, and caspase-3 (11, 39) . Activation of calpain and caspase-3 is important because both proteases are vital contributors to MV-induced diaphragmatic proteolysis and weakness (24, 27) . Therefore, identifying the ROS-producing pathways responsible for activation of these diaphragmatic proteases during prolonged MV is important. The current experiments demonstrate that mitochondrial ROS emission is a required upstream signal for MV-induced activation of both calpain and caspase-3. Although it is tempting to speculate that mitochondrial ROS emission activates calpain via increased levels of cytosolic free calcium, our experiments do not provide direct evidence for or against this supposition. Furthermore, although oxidative stress has been shown to promote caspase-3 activation in myotubes, our study does not distinguish the redox-sensitive signaling pathway that is responsible for this activation. Therefore, the ROStriggered signaling pathways responsible for activation of calpain and caspase-3 in the diaphragm during MV remain unknown and are an important direction for future work.
Furthermore, note that prevention of MV-induced mitochondrial ROS emission also protected against activa-tion of the 20S proteasome and the increased expression of atrogin-1 in the diaphragm. The cell signaling link to connect mitochondrial ROS emission and the activation of these key proteasome proteins remains unknown.
Importantly, our results also show that prevention of the MV-induced increase in mitochondrial ROS emission not only prevented protease activation but also attenuated MV-induced diaphragmatic atrophy and contractile dysfunction. Indeed, treatment of animals with the mitochondria-targeted antioxidant SS-31 was successful in preventing MV-induced atrophy in type I, IIa, and IIx/b fibers in the diaphragm (Fig. 4 ). Furthermore, prevention of MV-induced increases in mitochondrial ROS emission also provided partial protection against MV-induced decreases in diaphragmatic specific force production at both submaximal and maximal stimulation frequencies ( Fig. 3) . Together, these novel results indicate that protection against MV-induced mitochondrial ROS emission in the diaphragm protects this key inspiratory muscle from MV-induced weakness.
Conclusions and Clinical Implications. From a clinical perspective, the most important result from these experiments is the finding that treatment of animals with the mitochondriatargeted antioxidant SS-31 prevents the rapid onset of MV-induced diaphragmatic atrophy and contractile dysfunction. Given that MV-induced diaphragmatic weakness may contribute to the failure-to-wean syndrome, this finding has significant clinical implications and suggests that mitochondria-targeted antioxidants may have therapeutic potential in protecting the diaphragm from MV-induced weakness and may reduce weaning problems in some patients. SS-31 is currently undergoing clinical development as a novel mitochondria-targeted therapy by Stealth Peptides (Newton Centre, MA). The results of a recent phase I clinical trial with intravenous infusion of SS-31 demonstrated safety and tolerability with predictable linear pharmacokinetics that included doses exceeding the expected patient dose by several-fold. Clearly the use of SS-31 in prevention of MV-induced diaphragmatic weakness is an exciting possibility that warrants clinical investigation. Figure 7 . Calpain and caspase-3 activity in the diaphragm from control animals (CON) and mechanically ventilated animals with (MVSS) without (MV) mitochondria-targeted antioxidants. (A) Levels of the 145-kDa ␣-II spectrin breakdown product (SBPD 145 kDa) in diaphragm muscle following 12 hrs of MV. Note that SBDP 145 kDa is an ␣-II spectrin breakdown product that is specific to calpain cleavage of intact ␣-II spectrin and, therefore, the cellular level of SBDP 145 kDa can be used as a biomarker of in vivo calpain activity. (B) Levels of the 120-kDa ␣-II spectrin breakdown product (SBPD 120 kDa) in diaphragm muscle following 12 hrs of MV. Note that SBDP 120 kDa is an ␣-II spectrin breakdown product that is specific to caspase-3 cleavage of intact ␣-II spectrin and, therefore, the cellular levels of SBDP 120 kDa can be used as a biomarker of caspase-3 activity. The images above the histograms are representative Western blots of data from the three experimental groups. Values are means Ϯ SEM. *Different (p Ͻ .05) from both CON and MVSS. ‡ Different (p Ͻ .05) from MVSS (n ϭ 6/group).
Figure 8.
Ratio of actin to total sarcomeric protein levels in the diaphragm from control animals (CON) and mechanically ventilated animals with (MVSS) and without (MV) mitochondria-targeted antioxidants. Given that actin is preferentially degraded during disuse muscle atrophy, assessment of the ratio of actin to total sarcomeric protein levels provides a relative index of diaphragmatic proteolysis during prolonged MV. The image above the histogram is a representative Western blot of data from the three experimental groups. Values are means Ϯ SEM. *Different (p Ͻ .05) from both CON and MVSS (n ϭ 6/group).
